Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH

The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.

Fate Therapeutics Stock Price Increases 37.8%: Why It Happened

The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.

Why Fate Therapeutics Stock Is Skyrocketing Today

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells

Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report?

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled “The Power of hnCD16” on Friday, December 4, 2020 at 4:30 PM EDT.

Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

Fate Therapeutics Announces Participation in Upcoming Investor Conferences

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma

Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Tuesday, October 6, 2020 and 2:30 p.m. E.T.

Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

SAN DIEGO, Sept.  04, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

Fate Therapeutics Announces September Investor Events

SAN DIEGO, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Officer. Mr. Dulac comes to the Company from Celgene Corporation, where he most recently served as Vice President, Business Development & Strategy, and brings an extensive array of biopharmaceutical experience having served for over 20 years in positions in finance, business development, and product portfolio strategy.

Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient

Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

SAN DIEGO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020, at 11:30 a.m. EST.

Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July  29, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 5:30 p.m. ET to report its second quarter 2020 financial results and provide a corporate update.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Probably, but it depends on whether the company can deliver on its cost-cutting potential.

Could Fate Therapeutics Be a Millionaire-Maker Stock?

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients

Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

Cigna

Uber

Advance Auto Parts

Axis Capital

Bristol-Myers

Cannae Hlds

Cooper Companies

Enterprise Products Partners

Twenty-First Century Fox

Park Hotels & Resorts

Truist Financial

V.F.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from.

Notable Insider Buys Last Week: Cigna, Fox, Uber And More

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 7,108,796 shares of its common stock, which included 927,324 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.31 per share.  Aggregate gross proceeds from this offering, including exercise of the option, were approximately $201.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The cell therapy developer announced the next step for an important pipeline asset.

News for Fate Therapeutics Stock (FATE)